Drug resistance mediated by hypoxic bone marrow leukemia environment in chronic myelogenous leukemia
| Project/Area Number |
19790674
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Kyoto Prefectural University of Medicine |
|---|
Principal Investigator |
KURODA Junya Kyoto Prefectural University of Medicine, 医学研究科, 助教 (70433258)
|
|---|
| Project Period (FY) |
2007 – 2008
|
| Project Status |
Completed (Fiscal Year 2008)
|
| Budget Amount *help |
¥3,510,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥510,000)
Fiscal Year 2008: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2007: ¥1,300,000 (Direct Cost: ¥1,300,000)
|
|---|
| Keywords | 慢性骨髄性白血病 / 低酸素 / 骨髄ニッチ / Bcr-Abl / 解糖系 / Glyoxalase-I / チロシンキナーゼ阻害剤 / 分子標的治療 / Bcr-Ab1 |
|---|
| Research Abstract |
低酸素環境における慢性骨髄性白血病(CML)細胞の薬剤耐性メカニズムと解糖系依存、ならびに低酸素下での薬剤耐性克服における分子標的としての解糖系解毒酵素Glyoxalase-I阻害の重要性がin vitro、in vivoで明らかになった。
|
Report
(3 results)
Research Products
(16 results)
-
[Journal Article] The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias.2008
Author(s)
Kamitsuji Y, Kuroda J, Kimura S, Toyokuni S, Watanabe K, Ashihara E, Tanaka H, Yui Y, Watanabe M, Matsubara H, Mizushima Y, Hiraumi Y, Kawata E, Yoshikawa T, Maekawa T, Nakahata T, Adachi S.
-
Journal Title
Cell Death Differ 15
Pages: 1712-1722
Related Report
-
[Journal Article] ABT-737 is a useful component of combinatory chemotherapies for chronic myelogenous leukaemias with diverse drug resistance mechanisms.2008
Author(s)
Kuroda J, Kimura S,Andreeff M,Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R, Murotani Y, Matsumoto Y, Tanaka H, Strasser A, Taniwaki M, Maekawa T.
-
Journal Title
Br J Haematol 140
Pages: 181-190
Related Report
-
-
-
-
[Journal Article] Apoptosis-based dual molecular targeting by INNO-406, a second generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of anti-apoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.2007
Author(s)
Kuroda J, Kimura S, Strasser A, Andreeff M, O'Reilly LA, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R, Tabe Y, Taniwaki M, Maekawa T.
-
Journal Title
Cell Death Differ 14
Pages: 1667-1677
Related Report
-
[Journal Article] INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system and cyclosporine A augments its in vivo activity.2007
Author(s)
Yokota A, Kimura S, Masuda S, Ashihara E, Kuroda J, Sato K, Kamitsuji Y, Kawata E, Deguchi Y, Urasaki Y, Terui Y, Ruthardt M, Ueda T, Hatake K, Inui KI, Maekawa T.
-
Journal Title
Related Report
-
-
-
[Presentation] Glyoxalase-I inhibition eliminates hypoxia-adapted CML cells resistant to imatinib, dasatinib, and INNO-406.2008
Author(s)
Takeuchi M , Kimura S, Kuroda J, Ashihara E, Kawatani M, Osada H, Umezawa K, Yasui E, Imoto M, Tsuruo T, Hodohara K, Nakahata T, Fujiyama Y, Maekawa T
Organizer
The American Society of Hematology 50th Annual Meeting and Exposition
Place of Presentation
San Francisco, Calfornia,USA
Related Report
-
-
-
-
-
-
[Presentation] Glyoxalase-I Is a Potential Therapeutic Target for Chronic Myelogenous Leukemia Cells That Have Acquired Drug Resistancethrough Adaptation to Hypoxia.2007
Author(s)
Takeuchi M, Kuroda J, Kimura S, Ashihara E, Umezawa K, Yasui E, Kawatani M, Osada H, Hodohara K, Fujiyama Y, Maekawa T
Organizer
The 49th Annual Meeting of American Society of Hematology
Place of Presentation
Atlanta, Georgia, USA
Related Report
